Latest Breaking News On - Keisuke ejima - Page 1 : comparemela.com

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials

Credit Justin Hicks / IPB News Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed. Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed. To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing symptoms. But clinical trials on average get participants around five days after symptoms.

Justin hicksKeisuke ejimaIndiana universityNagoya university in aichiNagoya universityஜஸ்டின் ஹிக்ஸ்இந்தியானா பல்கலைக்கழகம்நாகோயா பல்கலைக்கழகம்

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials
wbaa.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbaa.org Daily Mail and Mail on Sunday newspapers.

Keisuke ejimaIndiana universityNagoya university in aichiNagoya universityஇந்தியானா பல்கலைக்கழகம்நாகோயா பல்கலைக்கழகம்

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials Unable to load the audio player. playpausemuteunmute Article origination IPBS-RJC To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing symptoms. Justin Hicks/IPB News Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed.Â Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed.Â

Keisuke ejimaJustin hicksIndiana universityNagoya university in aichiNagoya universityஜஸ்டின் ஹிக்ஸ்இந்தியானா பல்கலைக்கழகம்நாகோயா பல்கலைக்கழகம்

Study reveals contributing factor to inconsistent results in clinical trials for COVID-19 drugs

Study reveals contributing factor to inconsistent results in clinical trials for COVID-19 drugs Jul 8 2021 A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs. The study is led by Keisuke Ejima, an assistant research scientist at the Indiana University School of Public Health-Bloomington. A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs. Photo courtesy of Getty Images

Shingo iwamiShoya iwanamiKeisuke ejimaResearch scientistIndiana university school of public healthNagoya university in aichiIndiana university schoolNagoya universityAssistant research scientistஷிங்கோ இவமிஆராய்ச்சி விஞ்ஞானிஇந்தியானா பல்கலைக்கழகம் பள்ளி ஆஃப் பொது ஆரோக்கியம்இந்தியானா பல்கலைக்கழகம் பள்ளிநாகோயா பல்கலைக்கழகம்உதவியாளர் ஆராய்ச்சி விஞ்ஞானி

Targeted News Service

Targeted News Service
targetednews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from targetednews.com Daily Mail and Mail on Sunday newspapers.

Indiana universityUnited statesKeisuke ejimaTnsjou indiana universityWhat underlies inconsistent resultsClinical trialsஇந்தியானா பல்கலைக்கழகம்ஒன்றுபட்டது மாநிலங்களில்மருத்துவ சோதனைகள்